Regenerative medicine company Histogen has decided to begin Phase I clinical trials of its hair stimulating complex HSC660 for the treatment of diffuse hair loss in women.

The company made this decision after the product received approval from the US Food and Drug Administration (FDA).

HSC660 was developed as an injectable treatment for hair growth that utilises a subset of naturally-secreted growth factors.

Manufactured by purifying cell-conditioned media, the treatment is claimed to induce fibroblast cells to stimulate the hair follicle, new hair growth and sustained hair viability.

“Millions of women experience diffuse hair loss due to a range of causes, but the current treatment options are limited in their effectiveness.”

Histogen’s principal investigator Dr Kimberly Butterwick is a Dermatology Cosmetic Laser Medical Associates dermatologist. She is currently in the process of hiring trial participants.

The company plans to enrol 27 patients to evaluate the safety of the injectable HSC660 treatment in women to find indicators of treatment efficacy.

Butterwick said: “Millions of women experience diffuse hair loss due to a range of causes, but the current treatment options are limited in their effectiveness.

“The potential of a simple, injected treatment that stimulates stem cells in the scalp to create new hair could be life-changing. We are excited to kick off the first trial of this novel HSC660 treatment in women.”